Published by Josh White on 7th July 2026
(Sharecast News) - Coiled Therapeutics said on Tuesday that it had developed a next-generation lipid-based softgel formulation of AO-252, its first-in-class brain-penetrant TACC3 inhibitor, with first patient dosing expected in July 2026.
URL: http://www.digitallook.com/dl/news/story/36055844/...